

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Press Releases](#)

[About MSK](#) [Our Mission & Treatment](#)

[Refer a Patient](#)

## ABOUT US

[Our mission, vision & core values](#)


[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)



Memorial Sloan Kettering Cancer Center's Ronald DeMatteo, MD, served as the principal investigator of a

Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer

large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

This study was funded by the [National Cancer Institute](#).

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Price Transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center